Celiac Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Celiac Disease Market Outlook
Thelansis’s “Celiac Disease Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Celiac Disease treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Celiac
Disease Overview
Celiac
disease is an immune-mediated disorder characterized by small intestinal
enteropathy, systemic malabsorption and immune activation symptoms, and
autoantibodies to tissue transglutaminase (TTG). It is unique among autoimmune
diseases in that the trigger, dietary gluten, has been identified, and removing
it results in the resolution of symptoms and enteropathy in most patients. The
undiagnosed celiac disease might have severe consequences in children and adult
subjects. Celiac disease’s primary mechanism is an abnormal adaptive immune
response to gluten-derived peptides. Prolamines have been found to contain
critical epitopes presented by either HLA-DQ2 or HLA-DQ8 that induce a CD4+
T-lymphocyte response. Celiac disease can be severe as it can cause long-lasting
digestive problems and keep the body from getting all the necessary nutrients.
It can also affect the body outside the intestine.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment